Non Small Cell Lung Cancer (NSCLC)

Stage IV/Metastatic - 2nd Line - Immunotherapy

No Prior Therapy With PD-1/PD-L1

THOR0006
Phase III/II of Nivolumab with Vorolanib in Refractory Thoracic Tumors
PI: Wakelee NCTN

THOR0006
Phase III of Nivolumab with Vorolanib in Refractory Thoracic Tumors
PI: Wakelee NCTN

Failed Therapy PD-L1

LUN017
Phase III Atezolizumab +/- Cabozantinib vs Docetaxel Monotherapy in Metastatic Non-SmallCellLung Cancer
PI: Neal Sponsor: Hoffman La Roche

LUN017
Phase Ib/II Grapiprant +/- Pembrolizumab in Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
PI: Wakelee Arvs Therapeutics

ECOG-ACRIN-ECOG-ACRIN-ECOG-ACRIN
Phase II Cabozantinib +/- Nivolumab vs Standard Chemotherapy in Previously Treated Non-Squamous NSCLC
PI: Neal ECOG-ACRIN

KEY
Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu